openPR Logo
Press release

Deadline in Lawsuit for Investors in shares of Iterum Therapeutics plc (NASDAQ: ITRM) coming up on October 4th

09-14-2021 05:45 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A Deadline is coming up on October 4, 2021 in the lawsuit for certain investors in Iterum Therapeutics plc (NASDAQ: ITRM).

A Deadline is coming up on October 4, 2021 in the lawsuit for certain investors in Iterum Therapeutics plc (NASDAQ: ITRM).

A deadline is coming up on October 4, 2021 in the lawsuit filed for certain investors of Iterum Therapeutics plc (NASDAQ: ITRM) over alleged securities laws violations by Iterum Therapeutics plc.

Investors who purchased shares of Iterum Therapeutics plc (NASDAQ: ITRM) have certain options and there are strict and short deadlines running. Deadline: October 4, 2021. NASDAQ: ITRM stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Northern District of Illinois the plaintiff alleges on behalf of purchasers of Iterum Therapeutics plc (NASDAQ: ITRM) common shares between November 30, 2020 and July 23, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between November 30, 2020 and July 23, 2021, the Defendants made false and/or misleading statements and/or failed to disclose that the sulopenem NDA lacked sufficient data to support approval for the treatment of adult women with uUTIs caused by designated susceptible microorganisms proven or strongly suspected to be non-susceptible to a quinolone, that accordingly, it was unlikely that the FDA would approve the sulopenem NDA in its current form, that Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Iterum Therapeutics plc (NASDAQ: ITRM) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline in Lawsuit for Investors in shares of Iterum Therapeutics plc (NASDAQ: ITRM) coming up on October 4th here

News-ID: 2392930 • Views: 404

More Releases from Shareholders Foundation

Investigation announced for Investors in shares of Silverback Therapeutics, Inc. …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Silverback Therapeutics, Inc. Investors who purchased shares of Silverback Therapeutics, Inc. (NASDAQ: SBTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Silverback Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders. Seattle, WA
Lawsuit filed for Investors in shares of Vipshop Holdings Limited (NYSE: VIPS)
An investor, who purchased shares of Vipshop Holdings Limited (NYSE: VIPS), filed a lawsuit over alleged violations of Federal Securities Laws by Goldman Sachs and Morgan Stanley. Investors who purchased shares of Vipshop Holdings Limited (NYSE: VIPS) have certain options and for certain investors are short and strict deadlines running. Deadline: December 13, 2021. NYSE: VIPS investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Both Goldman
Investigation announced for Investors in Umpqua Holdings Corporation (NASDAQ: UM …
An investigation was announced concerning whether the takeover of Umpqua Holdings Corporation is unfair to NASDAQ: UMPQ stockholders. Investors who purchased shares of Umpqua Holdings Corporation (NASDAQ: UMPQ) and currently hold any of those ASDAQ: UMPQ shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain officers and directors of Umpqua Holdings Corporation breached their
Lawsuit filed for Investors in shares of Amarin Corporation plc (NASDAQ: AMRN)
An investor, who purchased shares of Amarin Corporation plc (NASDAQ: AMRN), filed a lawsuit in the over alleged violations of Federal Securities Laws by Amarin Corporation plc. Investors who purchased shares of Amarin Corporation plc (NASDAQ: AMRN) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2021. NASDAQ: AMRN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Ireland based

All 5 Releases


More Releases for Iterum

01-21-2021 | Health & Medicine
Fact.MR
Carbapenem-based Antibiotics Market to Exhibit 7% CAGR, with Sales of Tebipenem …
Incidence of bacterial infections with multidrug resistance is increasing rapidly, generating the need for novel, broad-spectrum carbapenem-based antibiotics for the treatment of various bacterial infections. Broad-spectrum carbapenem-based antibiotics such as tebipenem (Spero Therapeutics Inc.) and sulopenem (Iterum Therapeutics Inc.) are at late stage clinical development with expected launch of both in 2020 - 2021. Multidrug resistance to currently marketed carbapenem-based antibiotics is largely prevalent in the world. Also, expiry of
Pyelonephritis Treatment Market Size Estimated to Observe Significant Growth by …
A kidney infection, also known as pyelonephritis, is a type of urinary tract infection, wherein one or both kidneys are infected. The infection is caused by bacteria or a virus that commonly begins to infect urinary bladder and moves up to one or both the kidneys. Signs or symptoms of pyelonephritis can vary depending on age and could include confusion & back pain, chills & high fever, nausea & vomiting,
Urinary Tract Infections Therapeutics Pipeline Analysis 2018 by Key Players - Ac …
According to the research findings, a majority of the drug candidates for the treatment of UTIs are being developed as small molecules. It has been observed that the drugs that are being developed as small molecules are easy to manufacture with high production rate. Browse report sample at: https://www.psmarketresearch.com/market-analysis/utis-therapeutics-pipeline/report-sample It has been observed that a majority of the companies in the UTIs therapeutic pipeline are developing drug candidates by using advanced technologies
Pyelonephritis-Pipeline Review H2 2018
The Pyelonephritis Market which explains the future and present measurements of the market as for the patterns in play. The principle reason for the investigation is to legitimize the occurrences in the market by giving reader helpful and suitable bits of knowledge on the particulars of the market for the future extent of development and accessible prospects at the current situation with the market. The statistical surveying production additionally manages
Pyelonephritis-Pipeline Review H2 2018
The Pyelonephritis Market which explains the future and present measurements of the market as for the patterns in play. The principle reason for the investigation is to legitimize the occurrences in the market by giving reader helpful and suitable bits of knowledge on the particulars of the market for the future extent of development and accessible prospects at the current situation with the market. The statistical surveying production additionally manages
Urinary Tract Infections Therapeutics Pipeline Analysis 2018
Urinary tract infection (UTI) refer to a common bacterial infection disease, that occurs in either a community or healthcare setting. Clinically, UTIs are categorized as uncomplicated and complicated. Uncomplicated UTIs typically occur in a healthy adult non-pregnant woman and have no structural or neurological urinary tract abnormalities; these infections are differentiated into cystitis and pyelonephritis. Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/utis-therapeutics-pipeline/report-sample According to the research findings, a majority of the drug candidates for